ARCA biopharma (NASDAQ:ABIO) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of ARCA biopharma (NASDAQ:ABIO) in a report issued on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

ARCA biopharma Price Performance

Shares of NASDAQ ABIO opened at $1.81 on Monday. The business’s 50 day moving average is $1.96 and its two-hundred day moving average is $2.02. ARCA biopharma has a 52-week low of $1.74 and a 52-week high of $2.70.

ARCA biopharma (NASDAQ:ABIO) last released its earnings results on Wednesday, October 18th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter.

Institutional Trading of ARCA biopharma

A number of institutional investors have recently bought and sold shares of ABIO. HRT Financial LP acquired a new stake in shares of ARCA biopharma in the first quarter valued at approximately $28,000. Jane Street Group LLC acquired a new position in ARCA biopharma in the fourth quarter valued at $35,000. Charles Schwab Investment Management Inc. acquired a new position in ARCA biopharma in the first quarter valued at $30,000. Virtu Financial LLC purchased a new stake in shares of ARCA biopharma in the first quarter valued at about $55,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of ARCA biopharma in the second quarter valued at about $81,000.

ARCA biopharma Company Profile

ARCA biopharma, Inc, a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure.